IgAN
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2025
2026
2027
2028
2029
Fosun PharmaFXS6837 Dose 1
ADARx PharmaceuticalsADX-038 Dose Level 2
Clinical Trials (2)
Total enrollment: 105 patients across 2 trials
FXS6837 for the Treatment of IgAN Patients
Start: Mar 2026Est. completion: Nov 202760 patients
Phase 2Not Yet Recruiting
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
Start: Aug 2025Est. completion: Jun 202945 patients
Phase 2Recruiting
Related Jobs
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 105 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.